27.11.2012 Views

BioWorld® - Medical Device Daily

BioWorld® - Medical Device Daily

BioWorld® - Medical Device Daily

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information<br />

AGREEMENTS: Name Products Content of Agreement Date<br />

GE Healthcare research and<br />

collaboration 9/05<br />

development of nonnuclear<br />

contrast media<br />

agreement<br />

CIMYM<br />

development and licensing agreement 7/06<br />

BioSciences Inc. marketing rights for<br />

nimotuzumab in Japan<br />

Ingenuity Systems Ingenuity's Pathways expanded licensing 4/06<br />

Analysis<br />

agreement<br />

YM Biosciences development and licensing agreement 7/06<br />

Inc.<br />

marketing rights to<br />

TheraCIM<br />

(nimotuzumab) in Japan<br />

PRODUCTS ON MARKET: OTC pharmaceuticals, quasi-pharmaceuticals, pharmaceuticals, cosmetics,<br />

medical equipment, food products, beverages, diagnostic reagents,<br />

radiopharmaceuticals, radioisotope products, fine chemicals, packaging<br />

materials for pharmaceuticals and logistics services<br />

Dainippon Sumitomo Pharma Co. Ltd.<br />

2-6-8 Doshomachi, Chuo-ku<br />

Osaka 541-0045, Japan<br />

Phone: +81 06-6203-5321; Fax: +81 06-6233-2288<br />

Web: www.ds-pharma.co.jp<br />

KEY PERSONNEL: Yasuo Okamoto; Chairman<br />

Kenjiro Miyatake; President<br />

EMPLOYEES: 5,061 employees<br />

HISTORY: Created from the merger of Dainippon Pharmaceutical Co. Ltd. and<br />

Sumitomo Pharmaceuticals Co. Ltd. (10/05)<br />

Sumitomo Pharmaceuticals:<br />

Founded in February 1984 as a joint venture through merger of respective<br />

pharmaceutical divisions of Sumitomo Chemical Co. Ltd. and Inabata & Co.<br />

Dainippon Pharmaceutical:<br />

Founded in May 1897<br />

STOCK-FINANCIAL HISTORY: Sumitomo Pharmaceuticals:<br />

Net sales ¥136.915b (YE 04) compared to ¥138.282b (YE 03)<br />

Net income ¥12.048b (YE 04) compared to ¥11.168b (YE 03)<br />

Total assets ¥170.489b (YE 04) compared to ¥171.020b (YE 03)<br />

SUBSIDIARIES/DIVISIONS: Pharmaceuticals<br />

Animal science<br />

Food science<br />

Fine chemicals<br />

Laboratory products<br />

Dainippon Pharmaceutical:<br />

Net sales ¥170.842b (YE 04) compared to ¥172.161b (YE 03)<br />

Net income ¥7.967b (YE 04) compared to ¥6.364b (YE 03)<br />

Earnings per share ¥48.05/share (YE 04) compared to ¥88.02/share (YE 03)<br />

Total assets ¥193.237b (YE 04) compared to ¥187.416b (YE 03)<br />

BUSINESS STRATEGY: Manufacture, sell/purchase and import/export pharmaceuticals, diagnostics,<br />

medical devices, veterinary products, food additives, industrial chemicals<br />

and other chemical products<br />

Copyright ©2006 AHC Media ® 129

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!